Agenus (NASDAQ:AGEN) Downgraded by BidaskClub
Separately, B. Riley set a $33.00 price objective on shares of Triumph Bancorp and gave the stock a buy rating in a research note on Monday, April 22nd.
NASDAQ:AGEN opened at $2.40 on Friday. Agenus has a 1-year low of $1.54 and a 1-year high of $3.88. The business has a 50-day simple moving average of $2.72. The stock has a market capitalization of $322.22 million, a price-to-earnings ratio of -1.67 and a beta of 1.86.
Several hedge funds have recently added to or reduced their stakes in the business. Amalgamated Bank purchased a new position in shares of Agenus in the 4th quarter valued at approximately $30,000. Two Sigma Securities LLC purchased a new position in shares of Agenus in the 4th quarter valued at approximately $31,000. BNP Paribas Arbitrage SA raised its position in shares of Agenus by 80,579.2% in the 1st quarter. BNP Paribas Arbitrage SA now owns 19,363 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 19,339 shares during the last quarter. Legal & General Group Plc raised its position in shares of Agenus by 47.7% in the 4th quarter. Legal & General Group Plc now owns 21,674 shares of the biotechnology company’s stock valued at $52,000 after purchasing an additional 7,002 shares during the last quarter. Finally, Metropolitan Life Insurance Co. NY purchased a new position in shares of Agenus in the 4th quarter valued at approximately $80,000. 33.07% of the stock is owned by institutional investors and hedge funds.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Article: Dividend Achievers
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.